bearish
Microport Scientific (853.HK) - The Subsidiaries Would Be a Better Investment
293 Views21 Mar 2022 09:03
We analyzed the centralized procurement and other concerns on MicroPort. Due to its development mode, the subsidiaries are more attractive and better investment opportunities than the parent company.
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
- Industry Report - Insights on China Companion Diagnostics Market (Business Logic and Outlook)03 Aug 2022
- Pre-IPO Lepu Medical Technology - Lepu Is in a Difficult Position and Turning It Around Takes Time01 Aug 2022
- Microport Scientific (853.HK)-The “unique” Development Mode Leads to Lower-Than-Expected Performance04 Jul 2022
- Microport Scientific (853.HK) - The Subsidiaries Would Be a Better Investment21 Mar 2022
- Shanghai MicroPort MedBot Group (2252.HK) - Optimistic About the Outlook08 Feb 2022
- Peijia Medical (9996.HK) Vs Venus MedTech (2500.HK) Vs CardioFlow (2160.HK)-Pain Points and Solution25 Jan 2022
- Microport Scientific (853.HK) - The Favorable and the Unfavorable Aspects11 Oct 2021
x